Seeking Alpha

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate ...
Business Insider

Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM ...
FierceBiotech

Rectify's new lead candidate improves bile composition, reduces inflammation in mice with liver disease

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate: the small molecule RTY-694, which is meant to treat the rare liver disease ...
Morningstar

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

“These translational results demonstrate that Rectify’s PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,” said Rajesh Devraj, Ph ...